Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase

被引:65
|
作者
Hamstra, DA
Rice, DJ
Fahmy, S
Ross, BD
Rehemtulla, A
机构
[1] Univ Michigan, Sch Med, Dept Radiat Oncol, Med Ctr, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Med Ctr, Dept Pharmacol, Ann Arbor, MI 48105 USA
[3] Univ Michigan, Med Ctr, Dept Radiol, Ann Arbor, MI 48105 USA
[4] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1089/10430349950017356
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The use of cytosine deaminase (CD) in conjunction with 5-fluorocytosine (5-FC) has been studied for cancer gene therapy as a means of achieving tumor-specific generation of the toxic metabolite 5-fluorouracil (5-FU), Since 5-FC is frequently used as an antifungal agent, and because it has little or no efficacy as an antibacterial agent, we hypothesized that yeast CD (YCD) might be more efficient at utilizing 5-FC as a substrate and hence be a better choice for a CD/5-FC gene therapy strategy than the typically utilized bacterial CD (BCD), To that end Saccharomyces cerevisiae CD was cloned from yeast genomic DNA and expressed in vitro. Functional analysis of BCD and YCD expressed in COS-1 cells indicated that BCD and YCD both utilized cytosine with equal efficacy; however, 5-FC was an extremely poor substrate for BCD, with an apparent catalytic efficiency 280-fold lower than that observed for YCD, Retroviral infection of tumor cell lines in vitro indicated that the IC50 of 5-FC was 30-fold lower in PCD-infected cultures as compared with cultures infected with BCD retrovirus, In addition, when SCCVII murine squamous cell carcinoma cells were infected in vitro at low rates of infection (less than or equal to 10%) there was no significant cytotoxicity toward BCD-expressing cells while there was potent cytotoxicity to both YCD-expressing cells and "bystander cells" even at this low level of expression. Finally, stable BCD- or YCD-expressing SCCVII clones were developed and used in an orthotopic immune-competent model of head and neck cancer. Subsequent treatment with 5-FC followed by monitoring of tumor growth by noninvasive magnetic resonance imaging (MRI) and survival of animals indicated a growth delay during the course of 5-FC treatment for BCD-expressing tumors, which quickly regrew at the end of treatment. In contrast, YCD-expressing tumors exhibited not only a growth delay, which was of longer duration, but also in some cases frank tumor regression and complete cures occurred.
引用
收藏
页码:1993 / 2003
页数:11
相关论文
共 50 条
  • [1] Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy
    El-Sayed, Ashraf S. A.
    Mohamed, Nabil Z.
    Yassin, Marwa A.
    Amer, Mahmoud M.
    El-Sharkawy, Reyad
    El-Sayed, Nesma
    Ali, Mostafa G.
    HELIYON, 2022, 8 (09)
  • [2] Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expression Escherichia coli cytosine deaminase
    Li, ZW
    Shanmugam, N
    Katayose, D
    Huber, B
    Cowan, K
    Seth, P
    CANCER GENE THERAPY, 1996, 3 (06) : P81 - P81
  • [3] Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase
    Li, ZW
    Shanmugam, N
    Katayose, D
    Huber, B
    Srivastava, S
    Cowan, K
    Seth, P
    CANCER GENE THERAPY, 1997, 4 (02) : 113 - 117
  • [4] Computational Design of a Photosensitized Yeast Cytosine Deaminase for Directed Enzyme-Prodrug Therapy
    Blacklock, Kristin
    Yachnin, Brahm
    Woolley, G. Andrew
    Khare, Sagar
    PROTEIN SCIENCE, 2018, 27 : 122 - 122
  • [5] The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model
    MK Nyati
    Z Symon
    E Kievit
    KJ Dornfeld
    SD Rynkiewicz
    BD Ross
    A Rehemtulla
    TS Lawrence
    Gene Therapy, 2002, 9 : 844 - 849
  • [6] The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model
    Nyati, MK
    Symon, Z
    Kievit, E
    Dornfeld, KJ
    Rynkiewicz, SD
    Ross, BD
    Rehemtulla, A
    Lawrence, TS
    GENE THERAPY, 2002, 9 (13) : 844 - 849
  • [7] Conjugation of poly-L-lysine to bacterial cytosine deaminase improves the efficacy of enzyme/prodrug cancer therapy
    Li, Cong
    Wildes, Flonne
    Winnard, Paul, Jr.
    Artemov, Dmitri
    Penet, Marie-France
    Bhujwalla, Zaver M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (12) : 3572 - 3582
  • [8] Gene Directed Enzyme/Prodrug Therapy of Human Glioma Xenografts Using Mutant Escherichia coli Cytosine Deaminase
    Kaliberov, Sergey A.
    Krendelchtchikova, Valentina
    Della Manna, Debbie
    Sellers, Jeffrey C.
    Kaliberova, Lyudmila N.
    Black, Margaret E.
    Buchsbaum, Donald J.
    MOLECULAR THERAPY, 2006, 13 : S365 - S366
  • [9] Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine
    Van Rite, Brent D.
    Harrison, Roger G.
    CANCER LETTERS, 2011, 307 (01) : 53 - 61
  • [10] Use of the horseradish peroxidase gene for enzyme prodrug therapy in a head and neck cancer model.
    Tupper, J
    Stratford, MR
    Hill, SA
    Lewis, GS
    Wardman, P
    Tozer, GM
    Dachs, GU
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6252S - 6252S